Previous 10 | Next 10 |
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will be ...
2024-01-08 23:32:32 ET Summary BrainsWay has achieved a successful turnaround with positive adjusted EBITDA and cash flow in Q3/23. The company offers advanced TMS therapy devices and has numerous patents. There are plenty of growth drivers from reimbursement, new conditions, ...
2023-12-29 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced increased collab...
BrainsWay Ltd. (NASDAQ: BWAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.64% on the day to $3.27. Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally...
BURLINGTON, Mass. and JERUSALEM, Dec. 07, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced expanded availab...
2023-11-30 20:32:31 ET Summary BrainsWay's stock grew 300%, driven by a 60% year-over-year revenue increase and Deep TMS technology success, achieving positive cash flow. Deep TMS faces challenges: clinical variability, practicality issues, market competition, evolving payer cover...
BrainsWay Ltd. (NASDAQ: BWAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.64% on the day to $3.27. Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally...
2023-11-27 13:27:19 ET More on Markets BMO Capital Markets sets base-case S&P 500 target of 5,100 for 2024 Rate cuts, S&P upside and oil prices among BofA's key themes for 2024 VanEck highlights mid-caps as a potential sweet spot for investors For fur...
BrainsWay Ltd. (NASDAQ: BWAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.64% on the day to $3.27. Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally...
News, Short Squeeze, Breakout and More Instantly...
2024-07-16 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced its broad market...